Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Clinical trial NCT04982224 · TERMINATED
Trial details
- NCT number
- NCT04982224
- Sponsor
- Regeneron Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-09
- Primary completion
- 2025-10-15
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.